



EMVision Medical Devices Ltd  
 ACN 620 388 230  
 Suite 4.01, 65 Epping Rd  
 Sydney NSW 2113  
 02 8667 5337  
[contact@emvision.com.au](mailto:contact@emvision.com.au)

# ASX Release

## OVERSUBSCRIBED SHARE PURCHASE PLAN TO CLOSE EARLY

**EMVision Medical Devices Limited (ASX:EMV)** (“EMVision” or the “Company”) advises that the Share Purchase Plan (SPP), announced on 17 September 2025 and opened on 29 September, has received applications in excess of the maximum SPP of \$2 million.

In accordance with the terms of the SPP, the Company has determined to close the SPP early to minimise the scale back of applications.

The new effective closure date for the SPP is **5:00pm (AEDT) on Tuesday, 21 October 2025** (Revised Closing Date). EMVision advises that any applications received after the Revised Closing Date will not be accepted under the SPP and those application monies will be returned in full to the applicant in accordance with the terms of the SPP. EMVision will undertake a scale-back of applications received prior to the Revised Closing Date.

A revised timetable for the SPP is shown in the table below:

| Event                                                 | Date                                      |
|-------------------------------------------------------|-------------------------------------------|
| Record Date for SPP                                   | 7:00pm AEST on Tuesday, 16 September 2025 |
| Settlement of New Shares issued under the Placement   | Tuesday, 23 September 2025                |
| Allotment of New Shares issued under the Placement    | Wednesday, 24 September 2025              |
| Despatch of SPP Offer Booklet and Options Prospectus  | Monday, 29 September 2025                 |
| Closing Date of SPP                                   | 5:00pm AEDT on Tuesday, 21 October 2025   |
| Announcement of Results of SPP                        | Thursday, 30 October 2025                 |
| Allotment of SPP Shares and Options                   | Thursday, 30 October 2025                 |
| Despatch of Holding Statements – SPP Shares & Options | Thursday, 30 October 2025                 |

*These dates are indicative only and are subject to change without notice. Subject to the requirements of the Corporations Act, the ASX Listing Rules and any other applicable laws, EMVision reserves the right to amend the timetable, including extending the SPP offer period or accepting late applications (either generally or in particular cases) without notice.*

Authorised for release by the Board of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Andrew Keys  
Investors & Media  
+61 400 400 380  
andrew.keys@keysthomas.com

Scott Kirkland  
CEO and Managing Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## **About EMVision Medical Devices**

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane [www.emvisionmedical.com](http://www.emvisionmedical.com)

## **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

## **Inherent risks of Investment in Medical Device development Companies**

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.